Advertisement
 
YOU ARE HERE: LAT HomeCollectionsPe Corp
IN THE NEWS

Pe Corp

FEATURED ARTICLES
BUSINESS
June 13, 2000 | From Bloomberg News
Geron Corp. shares rose 15% after the biotechnology company said it would work with PE Corp.'s Celera Genomics to decipher which human genes play a role determining how undifferentiated stem cells grow into different kinds of tissues. Geron shares rose $3.88 to close at $30.13 on Nasdaq. Celera shares rose $1.75 to $110 in trading on the New York Stock Exchange.
ARTICLES BY DATE
BUSINESS
June 13, 2000 | From Bloomberg News
Geron Corp. shares rose 15% after the biotechnology company said it would work with PE Corp.'s Celera Genomics to decipher which human genes play a role determining how undifferentiated stem cells grow into different kinds of tissues. Geron shares rose $3.88 to close at $30.13 on Nasdaq. Celera shares rose $1.75 to $110 in trading on the New York Stock Exchange.
Advertisement
NEWS
February 16, 2000 | PETER G. GOSSELIN and PAUL JACOBS, TIMES STAFF WRITERS
Federal officials are investigating whether the government was overcharged for gene sequencing machines developed at Caltech and widely considered crucial to the coming genetic revolution. Both the government and private companies are using the machines in a race to decipher the human genetic code. The outcome of the competition could determine whether the medical miracles that are expected to flow from the decoding will end up in public or private hands.
NEWS
May 14, 2000 | PETER G. GOSSELIN and PAUL JACOBS, TIMES STAFF WRITERS
When the history of the just-dawning genetic revolution is finally written, a clunky-looking machine the size of a sidewalk trash can will play a starring role. The automated DNA sequencer is letting researchers quickly crack the biochemical code of life, an achievement that could one day turn incurable diseases into treatable ones. But the machine is at the vortex of a struggle over wealth, fame and, quite possibly, control of the genetic code itself.
NEWS
May 14, 2000 | PETER G. GOSSELIN and PAUL JACOBS, TIMES STAFF WRITERS
When the history of the just-dawning genetic revolution is finally written, a clunky-looking machine the size of a sidewalk trash can will play a starring role. The automated DNA sequencer is letting researchers quickly crack the biochemical code of life, an achievement that could one day turn incurable diseases into treatable ones. But the machine is at the vortex of a struggle over wealth, fame and, quite possibly, control of the genetic code itself.
BUSINESS
March 16, 2000 | Times Staff, Bloomberg News
The biotech group has taken a pounding, with the Amex sector index sliding 29% since it soared to a record early last week. But Wednesday, Wall Street analysts indicated the prognosis appears healthy for several stocks in the volatile sector, issuing several "strong buy" ratings, including: * PE Corp.-Celera Genomics Group (CRA; $146, down $8) at ING Barings, with a $300 target.
BUSINESS
April 11, 2000 | Bloomberg News
The volatile shares of PE Corp.'s Celera Genomics (ticker symbol: CRA) tumbled 23% on Monday as a scientist running a rival project to decode human DNA questioned Celera's claim to a major step forward in the process. The Norwalk, Conn., company's stock, which had soared to $276 in late February, fell $30.38 to close at $100 on the NYSE. Other genome-research shares also tumbled, including Myriad Genetics (MYGN), down $12.50 to $55, and Millennium Pharmaceuticals (MLNM), down $23.75 to $149.50.
BUSINESS
May 10, 2000 | Bloomberg News
Nexell Therapeutics Inc.'s surging stock made another strong advance Tuesday after the Irvine company said Japan's largest maker of distilled spirits will sell Nexell's biotechnology products in Asia. The stock, which has more than quadrupled so far this year, moved up 28% during the session before settling back to $5.66, a gain of 64 cents, or 13%, in heavy Nasdaq trading.
NEWS
June 27, 2000 | PAUL JACOBS, TIMES STAFF WRITER
To his admirers and shareholders, J. Craig Venter is a corporate wizard of gene deciphering, a magician of the genetic code. As president and chief scientific officer of Celera Genomics, his vision has allowed the 2-year-old company to lay claim to what is arguably the more complete of the two versions of the human genome--the genetic instruction manual for the human body.
BUSINESS
January 2, 2000 | By PAUL JACOBS
Who will make big news in the business world this year? Who will emerge from relative obscurity to become a major player? To start the new year, Times business reporters selected people from their beats who they believe will be among those to watch in 2000--in Southern California, across the country and around the world. Some are well known, having made big news in previous years. Others are not exactly household names but nevertheless are likely to make a major impact in their fields.
NEWS
February 16, 2000 | PETER G. GOSSELIN and PAUL JACOBS, TIMES STAFF WRITERS
Federal officials are investigating whether the government was overcharged for gene sequencing machines developed at Caltech and widely considered crucial to the coming genetic revolution. Both the government and private companies are using the machines in a race to decipher the human genetic code. The outcome of the competition could determine whether the medical miracles that are expected to flow from the decoding will end up in public or private hands.
BUSINESS
April 6, 2000 | From Times Wire Services
Beaten-down biotechnology shares surged Wednesday after President Clinton reassured the industry that its commercial gene discoveries could be patented. Among the biggest gainers were shares of companies specifically involved in research into the human genome--the recipe book of genes that form a person. PE Corp.-Celera soared $41.38 to $115, Human Genome Sciences surged $16 to $97, Millennium Pharmaceuticals leaped $21.36 to $143.36 and Sequenom rocketed $9.38 to $33.50.
BUSINESS
June 27, 2000
Here's a look at some biotech companies involved in human genome research and the development of drugs. Most of the companies are unprofitable and many have generated scant sales, but the sector has stirred tremendous investor enthusiasm because of the potential for scientific breakthroughs. Even with their recent rebounds, many of the stocks have come way down from their spring peaks. Which stocks do some of the sector analysts like?
Los Angeles Times Articles
|